Kalobios Pharmaceuticals, Inc.

Irm LLC

Amersham Biosciences Ab

Kenneth Luehrsen

Christopher Robert Bebbington

Geoffrey T Yarranton

Mark Baer

David Martinez

Christina Yi

Robert Elghanian

Jeng-Horng Her

Nenad Tomasevic

Peter Flynn

Vineet Gupta

Robert F Balint

Abhijit Mazumder

Varghese Palath

Carl Yamashiro

Jason Williams

Chang-Gong Liu

Zhijie John Gu

Swathi Sujatha-Bhaskar

David G Wang

David R Fermin

Ekaterina Pestova

Handy Yowanto

Todd Tuggle

Arkadiy Silbergleyt

Ramesh Ramakrishnan

Changming Li

Gretchen Kiser

Krishnamurthy Jayaraman

Buena Chui

The current invention relates to high-affinity antibodies to EphA3 that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.

Antibodies to EphA3

The invention provides anti-EGF-like module containing, mucin-like, hormone receptor-like 1 (EMR1) antibodies and methods of using such antibodies to treat EMR1-related diseases.

Anti-EMR1 antibodies

The current invention relates to high-affinity antibodies to Granulocyte-Macrophage Colony-Stimulating Factor that have reduced immunogenicity when administered to a human to treat diseases and method of using such antibodies.

Antibodies to granulocyte-macrophage colony-stimulating factor

The current invention provides high-affinity antibodies to thePcrV protein that have reduced immunogenicity when administered to treatinfections.

[object Object]

The present invention provides improved antibodies or antigen-binding molecules that specifically recognize and agonize the tyrosine receptor kinase B (TrkB) receptor, and methods of their use. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.

Anti-TrkB antibodies

The present invention provides methods of making antibodies having the binding specificity of a reference antibody. Antibodies generated by the methods of the inventions have at least one minimal essential binding specificity determinant from a heavy chain or light chain CDR3 from the reference antibody. The method can be used, e.g., in humanization procedures. The invention also provides libraries and antibodies made in accordance with the methods.

Antibody specificity transfer using minimal essential binding determinants

This invention relates to methods and compositions for determining single nucleotide polymorphisms (SNPs) in P450 genes. In preferred embodiments, self extension of interrogation probes is prevented by using novel non self-extension probes and/or methods, thereby improving the specificity and efficiency of P450 SNP detection in target samples with minimal false positive results. The invention thus describes a variety of methods to decrease self-extension of interrogation probes. In addition, this invention provides a unique collection of P450 SNP probes on one assay, primer sequences for specific amplification of each of the seven P450 genes and amplicon control probes to evaluate whether the intended p450 gene targets were amplified successfully. The invention also describes a variety of array platforms for performing the assays of the invention; for example: CodeLink&#x2122;, eSensor&#x2122;, multiplex arrays with cartridges etc., all described herein.

P450 single nucleotide polymorphism biochip analysis

Growing community of inventors

Half Moon Bay, CA, United States of America

Kenneth Luehrsen